LyphoMed
Executive Summary
Company says it has submitted an NDA for gallium nitrate for treatment of cancer-related hypercalcemia. The drug was developed through a research agreement with Memorial Sloan-Kettering Cancer Center. LyphoMed has exclusive worldwide marketing rights to gallium nitrate for all cancer-related indications.